Are Synthetic Compounds that Silence the Liver-X-Receptor the Next Generation of Anti-cancer Drugs?

Abstract

Glycolytic and lipogenic inhibitors have proven unsuccessful in cancer treatment strategies. In this issue of Cancer Cell, Flaveny and colleagues target the liver-X-receptor with an inverse agonist and show that key glycolytic and lipogenic genes are suppressed, leading to apoptosis of tumor cells without an effect on non-malignant cells.

• Authors: Knut R Steffensen
• Journal: Cancer cell (Cancer Cell) Vol. 28 Issue 1 Pg. 3-4 (Jul 13 2015) ISSN: 1878-3686 [Electronic] United States
• PMID: 26175408 (Publication Type: Journal Article, Comment)
• Copyright: Copyright © 2015 Elsevier Inc. All rights reserved.

Chemical References

• Antineoplastic Agents
• Orphan Nuclear Receptors
• Small Molecule Libraries
• Sulfonamides

Topics

• Animals
• Antineoplastic Agents (administration & dosage)
• Humans
• Lipogenesis (drug effects)
• Neoplasms (drug therapy)
• Orphan Nuclear Receptors (agonists)
• Small Molecule Libraries (administration & dosage)
• Sulfonamides (administration & dosage)